Comparative Pharmacology
Head-to-head clinical analysis: NORLESTRIN 21 1 50 versus TRI NORINYL 21 DAY.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NORLESTRIN 21 1 50 versus TRI NORINYL 21 DAY.
NORLESTRIN 21 1/50 vs TRI-NORINYL 21-DAY
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Combination oral contraceptive containing norethindrone (progestin) and ethinyl estradiol (estrogen). Inhibits ovulation via suppression of gonadotropins (LH, FSH). Enhances cervical mucus viscosity, reducing sperm penetration. Thins endometrium, decreasing implantation likelihood.
Combination oral contraceptive containing ethinyl estradiol and norethindrone. Ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects, increases viscosity of cervical mucus, alters endometrial morphology, and inhibits ovulation.
One tablet (1 mg norethindrone acetate/50 mcg ethinyl estradiol) orally once daily for 21 days, followed by 7 days off therapy.
One tablet (35 mcg ethinyl estradiol, 0.5 mg norethindrone for 7 days, 1 mg norethindrone for 9 days, 0.5 mg norethindrone for 5 days) orally once daily for 21 days, then 7 days off. Start on first day of menstrual period or first Sunday after onset.
None Documented
None Documented
Norethindrone terminal half-life: 5-14 hours; ethinyl estradiol terminal half-life: 10-20 hours. Clinical context: steady-state reached within 5-7 days, clinically significant for missed dose management.
Norethindrone: 5-14 hours; Ethinyl estradiol: 17-23 hours. Steady-state reached within 5-7 days; clinical relevance for missed dose timing and resumption of ovulation.
Norethindrone: renal (33% as metabolites), fecal (50%); ethinyl estradiol: renal (40% as glucuronide conjugates), fecal (60%)
Renal: ~50-60% (as metabolites); Fecal: ~30-40% (via bile); unchanged drug <1%.
Category C
Category C
Oral Contraceptive
Oral Contraceptive